Keytruda Pricing Added To Increased 2023 Spending, But ICER Sees Evidence

In identifying 10 drugs whose price increases added the most to US health care spending in 2023, ICER found Keytruda’s was backed by six studies. Gilead’s Biktarvy led the list of drugs whose increases lacked support.